Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).

Oncotarget - 10 Jan 2017

Wege Anja K, Weber Florian, Kroemer Alexander, Ortmann Olaf, Nimmerjahn Falk, Brockhoff Gero

Abstract excerpt

Cancer immunotherapy has been shown to enhance established treatment regimens. We evaluated the potential reinforcing effect of IL-15 in trastuzumab treated humanized tumor mice (HTM) which were generated by concurrent transplantation of neonatal NOD-scid IL2Rγnull mice with human hematopoietic stem cells (HSC) and HER2 positive breast cancer cells (metastasizing SK-BR-3, solid tumor forming BT474).We found that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyaluronan Receptors

Share to Immunomodulation

Share to Interleukin-15

Share to Receptors, IgG

Share to Trastuzumab

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 27835865
DOI: 10.18632/oncotarget.13159
PMCID: PMC5356837

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).PMID 27835865Read ↗

Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG miceSemantic proximity Read ↗

Humanized mouse model supports development, function, and tissue residency of human natural killer cellsSemantic proximity Read ↗

Immune humanized mice reconstituted with peripheral blood mononuclear cells or hematopoietic stem cells develop distinct MDA-MB-231 tumor immune microenvironmentsSemantic proximity Read ↗

Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes.Semantic proximity Read ↗

Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory ResponsesSemantic proximity Read ↗

A Novel Natural Killer Cell Expansion Technology for the Development of Cellular ImmunotherapiesSemantic proximity Read ↗

Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpressionSemantic proximity Read ↗

Therapeutic potential of interleukin‑15 in cancer (Review)Semantic proximity Read ↗

Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.Semantic proximity Read ↗

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.Semantic proximity Read ↗

CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumorsSemantic proximity Read ↗

NKTR-255, a polymer-conjugated IL-15, synergizes with CAR-T cell therapy to activate endogenous anti-tumor immunity and improve tumor controlSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.